Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $13.21

Neumora Therapeutics, Inc. (NASDAQ:NMRA)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $13.21, but opened at $13.77. Neumora Therapeutics shares last traded at $13.36, with a volume of 26,625 shares trading hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on NMRA shares. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Neumora Therapeutics in a research note on Thursday, September 12th. Mizuho started coverage on shares of Neumora Therapeutics in a research note on Monday, July 8th. They issued an “outperform” rating and a $20.00 target price for the company. HC Wainwright began coverage on shares of Neumora Therapeutics in a research note on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Neumora Therapeutics in a report on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $22.90.

Neumora Therapeutics Trading Up 1.3 %

The company’s fifty day moving average is $11.90 and its 200-day moving average is $11.18.

Neumora Therapeutics (NASDAQ:NMRA) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.37). As a group, analysts forecast that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, CFO Joshua Pinto sold 28,496 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $11.63, for a total value of $331,408.48. Following the sale, the chief financial officer now owns 210,469 shares in the company, valued at approximately $2,447,754.47. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Robert A. Lenz sold 30,788 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total transaction of $363,606.28. Following the sale, the insider now directly owns 339,205 shares in the company, valued at approximately $4,006,011.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua Pinto sold 28,496 shares of Neumora Therapeutics stock in a transaction dated Thursday, August 22nd. The shares were sold at an average price of $11.63, for a total value of $331,408.48. Following the completion of the transaction, the chief financial officer now owns 210,469 shares of the company’s stock, valued at approximately $2,447,754.47. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 90,926 shares of company stock worth $1,067,758. 26.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neumora Therapeutics

Hedge funds have recently bought and sold shares of the business. Avidity Partners Management LP raised its stake in shares of Neumora Therapeutics by 10.6% during the 4th quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock worth $33,940,000 after buying an additional 190,632 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Neumora Therapeutics in the 1st quarter worth $10,354,000. Callan Capital LLC raised its position in Neumora Therapeutics by 222.6% during the second quarter. Callan Capital LLC now owns 661,194 shares of the company’s stock worth $6,500,000 after acquiring an additional 456,207 shares during the period. Rhumbline Advisers lifted its holdings in Neumora Therapeutics by 488.3% during the second quarter. Rhumbline Advisers now owns 103,258 shares of the company’s stock valued at $1,015,000 after purchasing an additional 85,706 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Neumora Therapeutics during the second quarter valued at $566,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.